Implanet SA (DE:IM11)

FRANKFURT:IM11

IM11

Implanet SA

RESEARCH TOOLSreports

Want to see DE:IM11 full AI Analyst Report?

Implanet SA (IM11) Price & Analysis

― Followers

IM11 Stock Chart & Stats

€0.28

>-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.28

>-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.08 - €0.42

Previous CloseN/A

Volume0.00

Average Volume (3M)4.40K

Market Cap

€27.90M

Enterprise Value€30.82M

Total Cash (Recent Filing)€3.01M

Total Debt (Recent Filing)€5.92M

Price to Earnings (P/E)―

Beta-0.24

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding143,818,970

10 Day Avg. Volume3,845

30 Day Avg. Volume4,401

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)70.59

Price to Sales (P/S)2.29

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained top-line expansion—from 7.45M (2023) to 12.47M (2025)—indicates improving commercial traction for Implanet's implant systems and instruments. A multi-year revenue rebound supports scale benefits, stronger market penetration, and a clearer runway toward operating leverage if margins continue to improve.

Gross Margin ExpansionA sharp improvement in gross margin to ~55% shows the company is realizing better product mix, pricing or production efficiencies. Higher gross margins strengthen the structural ability to convert revenue into operating profits once fixed-cost absorption improves, enhancing long-term profitability potential.

Improving Cash Flow TrendOperating cash flow materially improved year-over-year, signalling progress toward cash generation. While still negative, the trend reduces near-term financing pressure and suggests operational fixes or higher revenue quality that could lead to sustainable positive cash flow in the medium term if maintained.

Bears Say

Persistent LossesDespite revenue and margin gains, the company remains materially unprofitable with a ~-35% net margin in 2025. Ongoing net losses mean equity holders bear dilution or funding risk until operating income turns positive, constraining long-term financial resilience and reinvestment capacity.

High Leverage / Thin EquityA very thin equity base relative to debt (debt-to-equity ~14.7x) leaves the balance sheet fragile. Elevated leverage limits strategic flexibility, increases refinancing risk in adverse conditions, and magnifies the impact of continued losses on solvency if cash generation doesn’t turn positive.

Negative Free Cash FlowConsistent negative free cash flow, about -2.1M in 2025, implies the business cannot self-fund growth or service obligations without external capital. Persistent FCF deficits create reliance on financing, raising dilution and execution risk until operations achieve sustained positive cash conversion.

IM11 FAQ

What was Implanet SA’s price range in the past 12 months?

Implanet SA lowest stock price was €0.08 and its highest was €0.42 in the past 12 months.

What is Implanet SA’s market cap?

Implanet SA’s market cap is €27.90M.

When is Implanet SA’s upcoming earnings report date?

Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 116 days.

How were Implanet SA’s earnings last quarter?

Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.

Is Implanet SA overvalued?

According to Wall Street analysts Implanet SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Implanet SA pay dividends?

Implanet SA does not currently pay dividends.

What is Implanet SA’s EPS estimate?

Implanet SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Implanet SA have?

Implanet SA has 143,818,970 shares outstanding.

What happened to Implanet SA’s price movement after its last earnings report?

Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.723%.

Which hedge fund is a major shareholder of Implanet SA?

Currently, no hedge funds are holding shares in DE:IM11

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Implanet SA

Implanet S.A., together with its subsidiaries, researches and develops, manufactures, and sells spinal and orthopedic implants. The company offers spinal and knee products. Its products include Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw systems for posterior fixation. The company also provides knee prostheses under the Madison name. Implanet S.A. has a strategic partnership with Shanghai Sanyou Medical Co, Ltd. The company was founded in 2006 and is based in Martillac, France.